FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1915023341> ?p ?o ?g. }

• W1915023341 abstract "Background Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are syndromes of severe respiratory failure that are associated with substantial mortality and morbidity. Artifical ventilatory support is commonly required and may exacerbate lung injury. Partial liquid ventilation (PLV) has been proposed as a less injurious form of ventilatory support for these patients. Although PLV has been shown to improve gas exchange and to reduce inflammation in experimental models of ALI, a previous systematic review did not find any evidence to support or refute its use in humans with ALI and ARDS. Objectives The primary objective of this review was to assess whether PLV reduced mortality (at 28 d, at discharge from the intensive care unit (ICU), at discharge from hospital and at one, two and five years) in adults with ALI or ARDS when compared with conventional ventilatory support. Secondary objectives were to determine how PLV compared with conventional ventilation with regard to duration of invasive mechanical ventilation, duration of respiratory support, duration of oxygen therapy, length of ICU stay, length of hospital stay, incidence of infection, long‐term cognitive impairment, long‐term health related quality of life, long‐ term lung function, long‐term morbidity costs and adverse events. The following adverse events were considered: hypoxia (arterial PO2 <80 mm Hg), pneumothorax (any air leak into the pleural space requiring therapeutic intervention), hypotension (systolic blood pressure < 90 mm Hg sustained for longer than two minutes or requiring treatment with fluids or vasoactive drugs), bradycardia (heart rate < 50 beats per minute sustained for longer than one minute or requiring therapeutic intervention) and cardiac arrest (absence of effective cardiac output). Search methods In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 10, 2012, in The Cochrane Library; MEDLINE (Ovid SP, 1966 to November 2012); EMBASE (Ovid SP, 1980 to November 2012) and CINAHL (EBSCOhost,1982 to November 2012) for published studies. In our original review, we searched until May 2004. Grey literature was identified by searching conference proceedings and trial registries and by contacting experts in the field. Selection criteria As in the original review, review authors selected randomized controlled trials that compared PLV with other forms of ventilation in adults (16 y of age or older) with ALI or ARDS, reporting one or more of the following: mortality; duration of mechanical ventilation, respiratory support, oxygen therapy, stay in the intensive care unit or stay in hospital; infection; long‐term cognitive impairment or health‐related quality of life; long‐term lung function or cost. Data collection and analysis Two review authors independently evaluated the quality of the relevant studies and extracted the data from included studies. Main results In this updated review, one new eligible study was identified and included, yielding a total of two eligible studies (including a combined total of 401 participants). Of those 401 participants, 170 received 'high'‐dose partial liquid ventilation (i.e. a mean dose of at least 20 mL/kg), 99 received 'low‐dose' partial liquid ventilation (i.e. a dose of 10 mL/kg) and 132 received conventional mechanical ventilation (CMV). Pooled estimates of effect were calculated for all those who received 'high'‐dose PLV versus conventional ventilation. No evidence indicated that 'high'‐dose PLV either reduced mortality at 28 d (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.79 to 1.85, P = 0.37) or increased the number of days free of CMV at 28 d (mean difference (MD) ‐2.24, 95% CI ‐4.71 to 0.23, P = 0.08). The pooled estimate of effect for bradycardia in those who received PLV was significantly greater than in those who received CMV (RR 2.51, 95% CI 1.31 to 4.81, P = 0.005). Pooled estimates of effect for the following adverse events－hypoxia, pneumothorax, hypotension and cardiac arrest－all showed a nonsignificant trend towards a higher occurrence of these events in those treated with PLV. Because neither eligible study addressed morbidity or mortality beyond 28 d, it was not possible to determine the effect of PLV on these outcomes. Authors' conclusions No evidence supports the use of PLV in ALI or ARDS; some evidence suggests an increased risk of adverse events associated with its use." @default.
• W1915023341 created "2016-06-24" @default.
• W1915023341 creator A5004083739 @default.
• W1915023341 creator A5016171088 @default.
• W1915023341 creator A5047342303 @default.
• W1915023341 creator A5056014782 @default.
• W1915023341 creator A5089550922 @default.
• W1915023341 date "2013-07-23" @default.
• W1915023341 modified "2023-09-26" @default.
• W1915023341 title "Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome" @default.
• W1915023341 cites W1503190002 @default.
• W1915023341 cites W1794971901 @default.
• W1915023341 cites W1964453580 @default.
• W1915023341 cites W1978960863 @default.
• W1915023341 cites W1985694271 @default.
• W1915023341 cites W1988808050 @default.
• W1915023341 cites W2002590876 @default.
• W1915023341 cites W2004143324 @default.
• W1915023341 cites W2004917927 @default.
• W1915023341 cites W2007468578 @default.
• W1915023341 cites W2008780228 @default.
• W1915023341 cites W2009574966 @default.
• W1915023341 cites W2009763230 @default.
• W1915023341 cites W2013854878 @default.
• W1915023341 cites W2017858621 @default.
• W1915023341 cites W2018645946 @default.
• W1915023341 cites W2027713786 @default.
• W1915023341 cites W2028072481 @default.
• W1915023341 cites W2037459166 @default.
• W1915023341 cites W2049480582 @default.
• W1915023341 cites W2061145890 @default.
• W1915023341 cites W2068854215 @default.
• W1915023341 cites W2086863044 @default.
• W1915023341 cites W2091210055 @default.
• W1915023341 cites W2094369021 @default.
• W1915023341 cites W2109734170 @default.
• W1915023341 cites W2111861407 @default.
• W1915023341 cites W2115626471 @default.
• W1915023341 cites W2132222325 @default.
• W1915023341 cites W2155082372 @default.
• W1915023341 cites W2159763561 @default.
• W1915023341 cites W2161328469 @default.
• W1915023341 cites W2164314191 @default.
• W1915023341 cites W2597070792 @default.
• W1915023341 cites W3086046566 @default.
• W1915023341 cites W4232548876 @default.
• W1915023341 cites W4233675525 @default.
• W1915023341 cites W4235425951 @default.
• W1915023341 cites W4247668599 @default.
• W1915023341 cites W4254029413 @default.
• W1915023341 cites W4294658238 @default.
• W1915023341 cites W43003498 @default.
• W1915023341 cites W2028024131 @default.
• W1915023341 doi "https://doi.org/10.1002/14651858.cd003707.pub3" @default.
• W1915023341 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6516802" @default.
• W1915023341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23881653" @default.
• W1915023341 hasPublicationYear "2013" @default.
• W1915023341 type Work @default.
• W1915023341 sameAs 1915023341 @default.
• W1915023341 citedByCount "20" @default.
• W1915023341 countsByYear W19150233412012 @default.
• W1915023341 countsByYear W19150233412013 @default.
• W1915023341 countsByYear W19150233412015 @default.
• W1915023341 countsByYear W19150233412016 @default.
• W1915023341 countsByYear W19150233412017 @default.
• W1915023341 countsByYear W19150233412018 @default.
• W1915023341 countsByYear W19150233412019 @default.
• W1915023341 countsByYear W19150233412020 @default.
• W1915023341 countsByYear W19150233412021 @default.
• W1915023341 countsByYear W19150233412022 @default.
• W1915023341 countsByYear W19150233412023 @default.
• W1915023341 crossrefType "journal-article" @default.
• W1915023341 hasAuthorship W1915023341A5004083739 @default.
• W1915023341 hasAuthorship W1915023341A5016171088 @default.
• W1915023341 hasAuthorship W1915023341A5047342303 @default.
• W1915023341 hasAuthorship W1915023341A5056014782 @default.
• W1915023341 hasAuthorship W1915023341A5089550922 @default.
• W1915023341 hasBestOaLocation W19150233411 @default.
• W1915023341 hasConcept C126322002 @default.
• W1915023341 hasConcept C127413603 @default.
• W1915023341 hasConcept C141983124 @default.
• W1915023341 hasConcept C177713679 @default.
• W1915023341 hasConcept C197934379 @default.
• W1915023341 hasConcept C200457457 @default.
• W1915023341 hasConcept C2776348555 @default.
• W1915023341 hasConcept C2776376669 @default.
• W1915023341 hasConcept C2777080012 @default.
• W1915023341 hasConcept C2777714996 @default.
• W1915023341 hasConcept C42219234 @default.
• W1915023341 hasConcept C71924100 @default.
• W1915023341 hasConcept C78519656 @default.
• W1915023341 hasConceptScore W1915023341C126322002 @default.
• W1915023341 hasConceptScore W1915023341C127413603 @default.
• W1915023341 hasConceptScore W1915023341C141983124 @default.
• W1915023341 hasConceptScore W1915023341C177713679 @default.
• W1915023341 hasConceptScore W1915023341C197934379 @default.
• W1915023341 hasConceptScore W1915023341C200457457 @default.
• W1915023341 hasConceptScore W1915023341C2776348555 @default.
• W1915023341 hasConceptScore W1915023341C2776376669 @default.
• W1915023341 hasConceptScore W1915023341C2777080012 @default.

• next